We measured serum concentration of neopterin in 198 patients (116 male and 82 female, mean age 68 ± 13 years) and 62 age-matched control subjects (37 male and 25 female, mean age 66 ± 10 years). Exclusion criteria were acute coronary syndrome, renal insufficiency, malignant diseases, collagen diseases and active systemic inflammatory diseases. Written informed consent was obtained from all patients, and Institutional Review
Board on human research approved the study protocol.
There were 46 patients with NYHA functional class I, 81 in class II, 53 in class III, and 18 in class IV. The etiologies of heart failure were identified as dilated cardiomyopathy in 57 (29%), ischemic heart disease in 40 (20%), valvular heart disease in 51 (26%), hypertensive heart disease in 14 (7%), and others in the remaining 36 (18%) patients.
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Blood samples were obtained on admission, and serum neopterin concentrations were measured by Neopterin ELISA kit (IBL, Hamburg, Germany) following the manufacture's recommendations. The minimum detectable concentration of neopterin was typically 0.7 nmol/L.
All patients were followed up for median follow-up period of 719 days (range 5 -1825 days) after discharge. The end points were 1) cardiac death, defined as death from progressive heart failure or sudden cardiac death and 2) re-hospitalization due to progressive heart failure. During follow-up periods, there were 55 cardiac events including 13 cardiac deaths and 42 re-hospitalizations for worsening heart failure. From receiver operating characteristic (ROC) curve analysis, we determined the cut off value of serum neopterin levels as 10 nmol/L.
Kaplan-Meier analysis clearly demonstrated that high neopterin group had a significantly higher incidence of cardiac events than low neopterin group (P < 0.0001 by a log-rank test).
Next, we classified CHF patients into 4 groups according to serum neopterin levels: 
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To determine risk factors for cardiac events, the Cox proportional hazard regression analysis was used. Variables with a P value less than 0.05 in the univariate analysis were entered into the multivariate Cox analysis. Levels of sodium, log (BNP) and log (neopterin)
were independent predictors for cardiac events in patients with CHF [sodium: HR 0.73, 95%CI 0.55-0.98, P = 0.0362; log (BNP): HR 1.89, 95%CI 1.14-3.12, P = 0.0133; log (neopterin): HR 1.70, 95%CI 1.16-2.50, P = 0.0068].
Although neopterin increases in many clinical states including acute coronary syndrome and CHF (2-4), prognostic value of serum neopterin level has not been previously examined in CHF. In the present study, we demonstrated that high serum neopterin level was associated with high cardiac events rates, and neopterin was an independent prognostic factor of future cardiac events by the multivariate Cox proportional hazard analysis. These data suggest that serum neopterin is useful for risk stratification of patients with CHF.
